Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2004-001383-46Phase 4Completed
Phase 4 trial of rivastigmine in Alzheimer's disease (AD), sponsored by Karolinska University Hospital. Primary endpoints: Optimal dose-escalation interval for rivastigmine and Impact of Helicobacter pylori infection on gastrointestinal side effects. Started Aug 2004; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2004-001383-46.